Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

First SYGNIS QualiPhi®-based Products Launched by QIAGEN

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
QualiPhi®, now renamed SensiPhi®, targets sophisticated applications for DNA amplification.

SYGNIS AG has announced that its partner QIAGEN has launched the first two products of a series of kits based on SYGNIS’ proprietary amplification technology QualiPhi® now renamed SensiPhi®.

The two kits, REPLI-g WTA Single Cell Kit and REPLI-g Cell WGA & WTA Kit, are available now and will be commercialized globally through QIAGEN’s established distribution channels. The product launches result from a global exclusive license agreement with QIAGEN signed in 2012.

“We are at the beginning of a series of product launches that we believe will establish our polymerase as the potential future gold standard for isothermal amplification of DNA”, Pilar de la Huerta, CEO of SYGNIS stated.

Huerta continued, “With the launch of the first products based on our proprietary technology, SYGNIS continues to deliver on its objectives. It is a mark of our success as a company to have our product commercialized by the world leader QIAGEN.”

“We are very pleased with the launch of our new kits based on the polymerase provided by SYGNIS”, commented Achim Ribbe, Vice President Corporate Business Development Licensing at QIAGEN. “The REPLI-g WTA Single Cell and REPLI-g Cell WGA & WTA address key user challenges in NGS and other downstream applications, where DNA sequence analysis is limited by small amounts down to single cells of available sample material. To drive adoption of NGS in the clinical space, QIAGEN is building a broad portfolio of universal products including the REPLI-g Single Cell Kits which are compatible with any major NGS platform and which also support our own integrated sample-to-insight GeneReader workflow currently in development.”

SensiPhi® is the second generation of a DNA polymerase that was licensed from the Spanish National Research Council (CSIC) in 2010. Due to its unique properties, first studies suggest that it has the potential to improve the amplifications of whole genomes and large stretches of DNA.

SYGNIS’ SensiPhi® is a high efficiency, high fidelity polymerase for DNA amplification which conveys the outstanding properties in terms of speed, accuracy and length of DNA fragments to be amplified.

It differs from PCR since it provides generic amplification of the complete genome, whereas PCR is designed to detect predefined target sequences, and therefore only amplifies specific, mostly very short fragments of the DNA.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS Signs Initial Distribution Agreement with FUNAKOSHI
TruePrime™ family for whole genome amplification without the need of synthetic random primers on stock and ready for distribution in Japan.
Thursday, March 05, 2015
SYGNIS Signs Initial Non-Exclusive Distribution Agreement with BioCat
TruePrime™ Single Cell WGA kit to be launched early 2015.
Tuesday, December 30, 2014
SYGNIS Announces Double Switch Technology Patent Deal with SYSTASY
Company reiterates strategic deals with leading industry partners.
Tuesday, May 13, 2014
SYGNIS Reports Financial Results for a Successful Fiscal Year 2013
First products launched based on QualiPhi® now renamed SensiPhi® in early 2014.
Wednesday, April 02, 2014
SYGNIS AG Successfully Completes Rights Offering and Private Placement
Company plans to use EUR 2.7 million to finance its operating business and further growth.
Monday, October 28, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Computer Model Could Explain how Simple Molecules Took First Step Toward Life
Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!